

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/081762 A1

(51) International Patent Classification:

A61K 35/74 (2015.01) *A61K 9/14* (2006.01)
A61K 35/742 (2015.01) *A61P 17/00* (2006.01)
A61K 47/26 (2006.01) *A61P 31/00* (2006.01)
A61K 35/747 (2015.01) *A61P 31/04* (2006.01)
A61K 9/00 (2006.01) *A61K 8/99* (2017.01)
A61K 9/06 (2006.01) *A61K 8/00* (2006.01)
A61K 9/19 (2006.01)

63/091,783

14 October 2020 (14.10.2020) US

(71) Applicant: **DERMBIONT, INC.** [US/US]; 451 D Street, Suite 908, Boston, Massachusetts 02210 (US).

(72) Inventors: **BRUCKER, Robert**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US). **HUANG, Yanjun**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US). **JOVANOVIĆ, Nikola**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US). **SAKHAMURI, Bhanu Prakash Chowdary**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US). **LISTER, Ida**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US). **ZHANG, Xuecheng**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US). **JAIN, Sanjay**; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US).

(21) International Application Number:

PCT/US2021/054856

(22) International Filing Date:

13 October 2021 (13.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

(54) Title: COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH FUNGI AND OTHER PATHOGENIC MICROBES




FIG. 1

(57) Abstract: Among other things, disclosed herein are compositions and methods for using human-isolated or synthetic *Alcaligenes faecalis*, *Bacillus altitudinis*, *Bacillus pumilus*, *Bacillus subtilis*, or *Janthinobacterium lividum*. Compositions may improve skin health. Methods may include applying human-isolated or synthetic *Alcaligenes faecalis*, *Bacillus altitudinis*, *Bacillus pumilus*, *Bacillus subtilis*, or *Janthinobacterium lividum* over a host or host area, such as skin or mucosa to minimize the presence of one or more pathogenic microbes, maximize therapeutic effects of one or more additional therapeutics, and/or improve health of a host or host area. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-isolated or synthetic *Alcaligenes faecalis*, *Bacillus altitudinis*, *Bacillus pumilus*, *Bacillus subtilis*, or *Janthinobacterium lividum* and an acceptable carrier. Compositions

[Continued on next page]

WO 2022/081762 A1

TAYLOR, Emma Jean Mildred; c/o DermBiont, Inc., 451 D Street, Suite 908, Boston, Massachusetts 02210 (US).

(74) **Agent: SMITH, Maria C.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7 Floor, Boston, Massachusetts 02210 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

and methods may include a probiotic or another microbe to maximize growth and/or metabolites (e.g., resulting from growth of a probiotic). Compositions and methods may include human-isolated or synthetic *Alcaligenes faecalis*, *Bacillus altitudinis*, *Bacillus pumilus*, *Bacillus subtilis*, or *Janthinobacterium lividum* metabolites.